LRRK2 and Parkinson disease: Although a recent randomized controlled trial failed to show any benefit from use of urate-elevating inosine treatment in early PD [64], urate measurement in LRRK2-NMC remains a promising prognostic marker of resistance/susceptibility to PD development, and application of urate-modifying treatments should be considered in early LRRK2-PD cases.